Tumor necrosis factor–blocker therapy persistence, gaps, and switching among patients with psoriatic arthritis

PMS16 Cost of Tumor Necrosis Factor Blocker Per Treated Psoriatic Arthritis Patient Using Drug Utilization Data from a US Managed Care Population

Value in Health ◽

10.1016/j.jval.2012.03.205 ◽

2012 ◽

Vol 15 (4) ◽

pp. A36

Author(s):

M. Bonafede ◽

C. Watson ◽

S.R. Gandra ◽

N. Princic ◽

K.M. Fox

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Drug Utilization ◽

Tumor Necrosis ◽

Utilization Data ◽

P023 Disseminated Histoplasmosis in a Patient with Crohn's Disease Under Tumor Necrosis Factor Blocker Therapy: An Unusual Case

The American Journal of Gastroenterology ◽

10.14309/01.ajg.0000613060.27726.48 ◽

2019 ◽

Vol 114 (1) ◽

pp. S6-S7

Author(s):

Sandro Ferreira ◽

Fernando Jorge Nóbrega ◽

Roberta Araujo ◽

Rodrigo Santana ◽

Leandra Ramalho ◽

...

Keyword(s):

Crohn’S Disease ◽

Tumor Necrosis Factor ◽

Crohn's Disease ◽

Tumor Necrosis ◽

Unusual Case ◽

Blocker Therapy ◽

Disseminated Histoplasmosis ◽

Recognition, Diagnosis, and Treatment of Histoplasmosis Complicating Tumor Necrosis Factor Blocker Therapy

Clinical Infectious Diseases ◽

10.1086/648724 ◽

2010 ◽

Vol 50 (1) ◽

pp. 85-92 ◽

Cited By ~ 108

Author(s):

Chadi A. Hage ◽

Suzanne Bowyer ◽

Stacey E. Tarvin ◽

Debra Helper ◽

Martin B. Kleiman ◽

...

Keyword(s):

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Diagnosis And Treatment ◽

Blocker Therapy ◽

Which treatments had been tapered or stopped in rheumatoid arthritis in long-term DAS28 remission following subcutaneous tumor-necrosis-factor blocker therapy? A retrospective experience on 43 patients

Joint Bone Spine ◽

10.1016/j.jbspin.2012.02.006 ◽

2012 ◽

Vol 79 (5) ◽

pp. 520-521

Author(s):

Sanae Ali Ou Alla ◽

Cedric Lukas ◽

Najia Hajjaj-Hassouni ◽

René Marc Flipo ◽

Bernard Combe ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Blocker Therapy ◽

Subcutaneous Tumor ◽

Das28 Remission ◽

National and regional dose escalation and cost of tumor necrosis factor blocker therapy in biologic-naïve rheumatoid arthritis patients in US health plans

Journal of Medical Economics ◽

10.3111/13696998.2013.856314 ◽

2013 ◽

Vol 17 (1) ◽

pp. 1-10 ◽

Cited By ~ 12

Author(s):

Amie T. Joyce ◽

Shravanthi R. Gandra ◽

Kathleen M. Fox ◽

Timothy W. Smith ◽

Michael W. Pill

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Dose Escalation ◽

Tumor Necrosis ◽

Health Plans ◽

Blocker Therapy ◽

Cost of tumor necrosis factor blocker per treated psoriatic arthritis patient using drug utilization data from a US managed care population

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2011.11.793 ◽

2012 ◽

Vol 66 (4) ◽

pp. AB189

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Drug Utilization ◽

Tumor Necrosis ◽

Utilization Data ◽

Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies

Rheumatology and Therapy ◽

10.1007/s40744-021-00337-5 ◽

2021 ◽

Author(s):

Ana-Maria Orbai ◽

M. Elaine Husni ◽

Dafna D. Gladman ◽

Ying Ying Leung ◽

Stefan Siebert ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

Pooled Analysis ◽

Phase 3 ◽

Factor Inhibitor ◽

PMS69 Tumor Necrosis Factor Blocker Dose Escalation among Biologic Naïve Rheumatoid Arthritis (RA) Patients in Commercial Managed Care Plans in the Two Years Following Therapy Initiation

Value in Health ◽

10.1016/j.jval.2012.03.258 ◽

2012 ◽

Vol 15 (4) ◽

pp. A46

Author(s):

M. Bonafede ◽

S.R. Gandra ◽

K.M. Fox ◽

K. Wilson

Keyword(s):

Rheumatoid Arthritis ◽

Tumor Necrosis Factor ◽

Managed Care ◽

Dose Escalation ◽

Tumor Necrosis ◽

Care Plans ◽

Therapy Initiation ◽

Association between tumor necrosis factor inhibitor (TNFi) therapy and changes in C-reactive protein (CRP), blood pressure, and alanine aminotransferase (ALT) among patients with psoriasis, psoriatic arthritis, or rheumatoid arthritis

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2015.02.004 ◽

2015 ◽

Vol 72 (5) ◽

pp. 917-919 ◽

Cited By ~ 5

Author(s):

Jashin J. Wu ◽

Christopher G. Rowan ◽

Judith D. Bebchuk ◽

Mary S. Anthony

Keyword(s):

Rheumatoid Arthritis ◽

Blood Pressure ◽

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Inhibitor ◽

C Reactive Protein ◽

Reactive Protein ◽

Factor Inhibitor ◽

Tumor necrosis factor-α in psoriasis and psoriatic arthritis: A clinical, genetic, and histopathologic perspective

Current Rheumatology Reports ◽

10.1007/s11926-004-0041-0 ◽

2004 ◽

Vol 6 (4) ◽

pp. 292-298 ◽

Cited By ~ 15

Author(s):

David Kane ◽

Oliver FitzGerald

Keyword(s):

Psoriatic Arthritis ◽

Tumor Necrosis Factor ◽

Tumor Necrosis ◽

Tumor Necrosis Factor Α ◽

Clinical Genetic ◽

Factor Α ◽